Recruiting

Observational Study

Sponsor:

Insel Gruppe AG, University Hospital Bern

Code:

NCT01257269

Conditions

Thrombotic Thrombocytopenic Purpura

Congenital Thrombotic Thrombocytopenic Purpura

Familial Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura, Congenital

Upshaw-Schulman Syndrome

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Observation

Study Details

Brief summary:

Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13 gene mutations.

Although considered a monogenic disorder the clinical presentation in Upshaw-Schulman syndrome patients varies considerably without an apparent genotype-phenotype correlation. In 2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family members to identify possible triggers of acute bouts of TTP, to document individual clinical courses and treatment requirements as well as possible side effects of long standing plasma substitution, e.g. alloantibody formation or viral infections.

Conditions

Thrombotic Thrombocytopenic Purpura

Congenital Thrombotic Thrombocytopenic Purpura

Familial Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura, Congenital

Upshaw-Schulman Syndrome

Study ID

NCT01257269

Start date

Oct, 2006

Status verified date

Oct, 2023

Completion date

Oct, 2030

Anticipated

Primary completion date

Oct, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Severe ADAMTS13 deficiency ( ≤ 10% activity) and no ADAMTS 13 inhibitor on two or more occasions at least one month apart
  • Being a family member of a confirmed or suspected patient
  • Molecular analysis of ADAMTS13 gene with one or more mutations and/or positive infusion trial (full recovered ADAMTS13 activity after infused fresh frozen plasma (FFP) with a plasma half-life of 2-4 days)

Study Design

Enrollment

450 participants

Anticipated

Interventions and Outcome Measures

Arms

1

Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency

2

Family members of patients with confirmed hereditary TTP

Interventions

Observation

No interventions planned: treatment of patients at the discretion of the treating/responsible physician

Primary outcome measure

  • Clinical presentation and disease course in hereditary TTP [ Time Frame: every year until death ]

Central Contacts and Locations

Central contacts

Locations

University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901

Recruiting

Oklahoma City, Oklahoma, United States, 73126-0901

Contacts

Principal Investigator:

James N. George, M.D.

More Information

Sponsor

Insel Gruppe AG, University Hospital Bern

Last update posted

Oct 11, 2023

Last verified

Oct, 2023

Keywords

  • Thrombotic thrombocytopenic purpura
  • ADAMTS13
  • Von Willebrand factor
  • Von Willebrand factor cleaving protease
  • Thrombocytopenia
  • Hemolytic anemia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern on 2023-10-11.